Axitinib Fails to Improve Survival in Metastatic Colorectal Cancer

Adding the VEGF inhibitor axitinib to first-line treatment of FOLFOX-6 for metastatic colorectal cancer failed to improve progression-free and overall survival.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news